NCT06663176View on ClinicalTrials.gov

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

February 5, 2026

Study Completion Date

May 5, 2026

Conditions

Non-Cystic Fibrosis Bronchiectasis

Interventions

DRUG

RESP302

Nitric Oxide agent

DRUG

RESP303

Nitric Oxide agent

Trial Locations (1)

Unknown

RECRUITING

ARENSIA Exploratory Medicine, Kyiv

All Listed Sponsors

lead

Thirty Respiratory Limited

INDUSTRY